A novel CAR Tcell therapy for T/NKcell lymphomasreceivedFDAsafetoproceedforPhase1trials,aprofoundadvancementfromthe7existingCAR-Ttherapies,developedatUTMDAndersonCancerCenter, canbemanufacturedanddeliveredin3and11daysrespectively,
← News
Public Health Systems Public Health Systems Health
Novel CAR T cell therapy moves into clinical studies
7FDA-Approved New therapy targets T/NKcell lymphomas unlike existing CAR T
3 days Manufacturing time
11 days Deliverywindow
Type1diabetes,Multiplesclerosis Potentialnew applications